Non-diabetic chronic kidney disease with subclinical metabolic acidosis Bicarbonate, urine TGF-beta, urine ammonium, chronic kidney disease
Conditions
Interventions
Oral sodium bicarbonate 0.8 mEq per kg(lean body weight) per day of Sodamint 300 mg per tablet (HCO3 3.7 mEq per tablet) for 12 weeks,Standard of care
Experimental Drug,No Intervention No treatment
Sodium bicarbonate,Control
Sponsors
Department of Medicine, Phramongkutklao Hospital and College of Medicine
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1.Age > 18 years old 2.Non-diabetic CKD stage 3-4 3.Normal serum bicarbonate (HCO3 22-26 mEq/L)
Exclusion criteria
Exclusion criteria: 1.Use of chronic daily oral alkali (such as sodium bicarbonate, sodium citrate, potassium citrate, etc) 2.Serum potassium < 3.3 or > 5.5 mEq/L 3.Self-reported vegetarian 4.New York Heart Association Class 3 or 4 heart failure symptom 5.History of staghorn calculi 6.Active glomerular disease requiring immunosuppressive agents 7.Kidney transplant patient 8.Pregnancy
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| change of urinary TGF-beta at 12 weeks after treatment pg/ml | — |
Secondary
| Measure | Time frame |
|---|---|
| UACR at 12 weeks after treatment mg/g,Serum HCO3 at 12 weeks after treatment mEq/L,Urine pH at 12 weeks after treatment -,Blood pressure at 12 weeks after treatment mmHg,Body weight at 12 weeks after treatment kg | — |
Countries
Thailand
Contacts
Public ContactNipon Ngupis
Phramongkutklao Hospital and College of Medicine
Outcome results
None listed